Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation  by Pilati, Camilla et al.
Cancer Cell
ArticleGenomic Profiling of Hepatocellular Adenomas
Reveals Recurrent FRK-Activating Mutations
and the Mechanisms of Malignant Transformation
Camilla Pilati,1,2 Eric Letouze´,3 Jean-Charles Nault,1,2 Sandrine Imbeaud,1,2 Anaı¨s Boulai,1,2 Julien Calderaro,1,2,4
Karine Poussin,1,2 Andrea Franconi,1,2 Gabrielle Couchy,1,2 Guillaume Morcrette,1,2 Maxime Mallet,1,2 Saı¨d Taouji,5
Charles Balabaud,5 Benoit Terris,6 Fre´de´ric Canal,7 Vale´rie Paradis,8 Jean-Yves Scoazec,9 Anne de Muret,10
Catherine Guettier,11,12 Paulette Bioulac-Sage,5,13 Eric Chevet,5 Fabien Calvo,14 and Jessica Zucman-Rossi1,2,15,*
1INSERM, UMR-1162, Ge´nomique fonctionnelle des tumeurs solides, IUH, 75010 Paris, France
2Labex Immuno-oncology, Universite´ Paris Descartes, Sorbonne Paris Cite´, Faculte´ de Me´decine, 75006 Paris, France
3Programme Cartes d’Identite´ des Tumeurs, Ligue Nationale Contre le Cancer, 75013 Paris, France
4Department of Pathology, Assistance Publique-Hoˆpitaux de Paris, CHU Henri Mondor, 94000 Cre´teil, France
5INSERM, UMR-1053, Universite´ de Bordeaux, 33076 Bordeaux, France
6Department of Pathology, Assistance Publique-Hoˆpitaux de Paris, Cochin Hospital, 75014 Paris, France
7Institut Cochin, INSERM U1016, Universite´ Paris Descartes, CNRS UMR8104, 75014 Paris, France
8Department of Pathology, Assistance Publique-Hoˆpitaux de Paris, Beaujon Hospital, Universite´ Paris Diderot, 92210 Clichy, France
9Department of Pathology, Edouard Herriot Hospital, 69437 Lyon, France
10Department of Hepatogastroenterology, Centre Hospitalier de Tours, Trousseau Hospital, 37044 Tours, France
11Department of Pathology, Assistance Publique-Hoˆpitaux de Paris, CHU Biceˆtre, 94275 Le Kremlin-Biceˆtre, France
12Department of Pathology, Assistance Publique-Hoˆpitaux de Paris, CHU Paul Brousse, 94800 Villejuif, France
13Department of Pathology, CHU de Bordeaux, Pellegrin Hospital, 33076, Bordeaux, France
14Institut National du Cancer, INCa, 92513 Boulogne, France
15Assistance Publique-Hoˆpitaux de Paris, Hoˆpital Europe´en Georges-Pompidou, 75015 Paris, France
*Correspondence: jessica.zucman-rossi@inserm.fr
http://dx.doi.org/10.1016/j.ccr.2014.03.005SUMMARYHepatocellular adenomas (HCA) are benign liver tumors predominantly developed in women using oral con-
traceptives. Here, exome sequencing identified recurrent somatic FRKmutations that induce constitutive ki-
nase activity, STAT3 activation, and cell proliferation sensitive to Src inhibitors. We also found uncommon
recurrent mutations activating JAK1, gp130, or b-catenin. Chromosome copy number and methylation
profiling revealed patterns that correlated with specific gene mutations and tumor phenotypes. Finally, inte-
grative analysis of HCAs transformed to hepatocellular carcinoma revealed b-catenin mutation as an early
alteration and TERT promoter mutations as associated with the last step of the adenoma-carcinoma transi-
tion. In conclusion, we identified the genomic diversity in benign hepatocyte proliferation, several therapeutic
targets, and the key genomic determinants of the adenoma-carcinoma transformation sequence.INTRODUCTION
Hepatocellular adenomas (HCA) are rare benign tumors mainly
developed in women after 2 years of oral contraceptive useSignificance
Malignant transformation of benign adenoma into malignant c
types. Adenoma-carcinoma transition is crucial for the patient
anisms involved. Here, we performed an integrated genomic
gene mutations, we identified recurrent somatic mutation ac
induce STAT3 activation and cell proliferation targetable by S
in hepatocellular carcinoma, we identifiedCTNNB1 and TERT p
tively, involved in adenoma-carcinoma transition. In conclusio
tification of adenomas with the highest risk of malignant trans
428 Cancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc.(Rooks et al., 1979). HCA are also related to other risk factors
(obesity, vascular diseases, and androgen and alcohol intake)
or to different genetic diseases (McCune-Albright syndrome,
glycogen storage disease type 1a, and maturity-onset diabetesarcinoma is frequently observed in several epithelial tumor
prognosis; however, little is known on the molecular mech-
analysis of hepatocellular adenomas (HCA). Among several
tivating FRK, a Src-like kinase. FRK-activating mutations
rc inhibitors. Focusing on malignant transformation of HCA
romotermutations as early and late genomic events, respec-
n, we propose to introduce targeted therapies and an iden-
formation in clinical practice.
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Genomics of Hepatocellular Adenomaof the young type 3 diabetes caused by HNF1A germline muta-
tion) (Calderaro et al., 2013; Nault et al., 2013a). Bleeding and
malignant transformation to hepatocellular carcinoma (HCC)
can occur as severe complications observed, respectively, in
30%–50% and 5% of the cases. In the past 10 years, we identi-
fied four major molecular subgroups of HCA defined by (1) muta-
tions inactivating HNF1A (H-HCA, 35% of the HCA) (Bacq et al.,
2003; Bluteau et al., 2002; Jeannot et al., 2010), (2) activation of
b-catenin by mutations in exon 3 (bHCA, 15%) (Chen et al.,
2002), (3) inflammatory phenotype with STAT3 activation
(IHCA, 50%) (Bioulac-Sage et al., 2009; Zucman-Rossi et al.,
2006), and (4) the remaining unclassified tumors (UHCA, 10%)
(Bioulac-Sage et al., 2009) (See Experimental Procedures for de-
tails on molecular group assessment.). Among bHCA, half dis-
played both inflammatory and b-catenin-activated phenotypes
(bIHCA). Inflammatory adenomas (IHCA) are caused by IL6ST
somatic mutation activating gp130 in 60% of the cases (Poussin
et al., 2013; Rebouissou et al., 2009), whereas other IHCA are
mutated for STAT3 itself (Pilati et al., 2011) or GNAS (Nault
et al., 2012), but in the remaining 30% of the cases no mutations
were identified yet. This molecular classification is currently
accepted in clinical practice using either immunohistochemical
markers (Bioulac-Sage et al., 2007, 2009) or in radiology at mag-
netic resonance imaging (Laumonier et al., 2008), and it has
dramatically improved the diagnosis and prognostic assessment
of HCA.
The aim of this work was to better characterize genomic alter-
ations causing benign proliferation of hepatocytes and their
malignant transformation to improve the molecular classification
and identify oncogenic events useful to propose a more person-
alized care of HCA patients in the future.
RESULTS
Spectrum of Mutations Identified by Exome Sequencing
We analyzed a series of 250 tumors from 195 patients including
223 classical HCAs without any suspicion of malignancy, 18
borderline lesions between HCA and HCC (HCA/HCC), and
nine cases of HCCs derived from HCA malignant transformation
(HCC on HCA); clinical, histological, and molecular features are
described in Tables S1 and S2 (available online). Among them,
whole-exome sequencing was performed using a SureSelect
Enrichment System (Agilent Technologies) and a HiSeq instru-
ment (Illumina) (see Supplemental Experimental Procedures).
Tumor and corresponding nontumor DNA was sequenced in
35 classical HCAs developed in 25 patients, including nine
H-HCAs, 11 IHCAs, four bHCAs, and four bIHCAs mutated in
exon 3 of CTNNB1, and seven UHCAs (Table S3). One IHCA
and one UHCA displayed a mutation of CTNNB1 located in
exon 7 and were reclassified as bIHCA and bHCA, respectively
(see below). The average coverage of each base in the targeted
regions was 70-fold (Figure S1). Somatic mutations were sys-
tematically verified using integrative genomics viewer inspection
and/or Sanger sequencing (see Supplemental Experimental Pro-
cedures and Table S4). This strategy led to the validation of 508
somatic mutations in the 35 tumors; among them, 264 (52%)
were predicted to have damaging consequences at the protein
level, whereas 124 (24%) were silent and 120 (24%) were pre-
dicted to be benign functionally using PPH2 (Polyphen-2) soft-ware (Figure 1A). The mean number of predicted damaging
mutations was 7.5 events per HCA tumor; it was not significantly
variable in the different HCAmolecular subgroups (Figure S1) but
lower than that observed in hepatocellular carcinoma (41 events
per HCC [Guichard et al., 2012], p < 0.0001). Analysis of the
spectrum of nucleotide mutations identified a high frequency
of transversions with a predominance of G>T changes that accu-
mulated on nontranscribed strand in all subgroups (Figure 1B).
This spectrum of nucleotide change was similar to that observed
in the exome sequence of classical HCC (Guichard et al., 2012),
suggesting that both benign and malignant hepatocyte prolifer-
ation could be promoted by exposure to genotoxic agents that
still remain to be identified in dedicated epidemiological studies.
Exome sequencing of the 35 classical HCAs identified recur-
rent mutations in nine different genes (Figure 1C). CTNNB1,
IL6ST, HNF1A, and FRK were mutated in at least three HCA tu-
mors, and they were validated in the whole series of 250 tumors
(Figure 1D; Table S5; Figure S1). SLCO1B3, KPNA4, ALK,
DDX11, and KIAA1109 were mutated in only two tumors repre-
senting seven different HCAs. Because these gene mutations
were not associated with specific phenotype, they were not
further screened in the entire series of tumors. Overall, a muta-
tion occurring in a gene recurrently mutated was identified in
205/250 (82%) of the HCA cases (Figure 1D). HNF1A and
CTNNB1 mutations were identified in all H-HCA and 33/35
bHCAs, respectively. Twenty-eight of 41 bIHCAs harbored
mutations in CTNNB1 and IL6ST. Inflammatory adenomas dis-
played mutations in the known drivers IL6ST, STAT3, and
GNAS, but also novel mutations in FRK and JAK1.
Among our whole series, the presence of two or more nodules
synchronously developed in the same patient was observed in
49% of the cases (Table S1). Exome sequencing of 10 pairs of
HCAs developed in 10 patients revealed in nine of these ten
cases that the two tumors belonged to the same molecular sub-
group: in four cases both adenomas were mutated forHNF1A, in
three cases both tumors were IHCA (IL6ST mutated and FRK in
one pair each, IL6ST and JAK1 in the last pair), in one case both
tumors were CTNNB1 mutated, and in the last patient both tu-
mors remained unclassified (Table S6). In the remaining patient
one HCA was inflammatory, whereas the second HCA was un-
classified. However, in nine of the ten cases, no common nucle-
otide mutations were identified among the paired adenomas,
suggesting an independent development of the tumors. In the
only pair with commonmutations, the two H-HCA tumors shared
one HNF1A mutation (Q211P) and a somatic substitution in
HDAC4 (T1055R). Interestingly, the two nodules were joined
and they accumulated different private alterations, including
inactivation of the second allele ofHNF1A (Table S6), suggesting
that HNF1A monoallelic inactivation added to an HDAC4 muta-
tion could be an early event in the history of this case.
FRK-Activating Mutations in IHCA
Among the 35 HCAs analyzed by exome sequencing, three
different IHCAs exhibited a somatic mutation of the fyn-related
kinase (FRK, also known as RAK). FRK is a non-receptor-tyro-
sine kinase related to the Src kinase family, first proposed as a
tumor suppressor in breast cancer cells (Yim et al., 2009). In
the whole series of 250 tumors, we identified a heterozygous
somatic FRK mutation in eight additional IHCAs and one bIHCACancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc. 429
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Figure 1. Profiles of Mutations in HCA Identified by Exome Sequencing
(A) Distribution of the 508 somaticmutations in the 35HCA tumors according to their functional consequences (damaging, benign, and synonymous) predicted by
PPH2 (Polyphen-2). Asterisk (*) indicates HCA with CTNNB1 exon 7 mutations.
(B) Type of mutations on the transcribed (pink) and the nontranscribed (blue) strands for the 455 nucleotide substitutions identified in exome sequencing of 35
HCAs (means with 95% CI; two-tailed Mann-Whitney test).
(C) Genes recurrently mutated in classical HCA with damaging consequences.
(D) Somatic mutations (blue boxes) identified in 250 tumors (columns) among seven classical HCA-altered genes (rows). The number of events per gene is
indicated on the left.
See also Figure S1 and Tables S1, S2, S3, S4, S5, and S6.
Cancer Cell
Genomics of Hepatocellular Adenoma(Figure 1D). All FRKmutations were located in the tyrosine kinase
catalytic domain, and two hot spots were identified: an amino
acid substitution located at codon 346 in four cases and eight
small in-frame deletions/insertions at codons V378 and/or
F379 in eight cases (Figure 2A; Table S5). In one case (1130),
we identified two nucleotide mutations that led to amino acid
substitutions at codons 346 and 350 carried by the same allele.
Overall, FRK was the second most frequently mutated gene in
our series of IHCA (12/118, 10%).
No recurrent FRKmutations are currently described in tumors.
In HCA, the mutation pattern including two hot spots and in-
frame deletion/insertion suggested that FRK mutations could
have gain of function. To test this hypothesis, we reproduced
six different mutants identified in IHCA by site-directed muta-
genesis in a FRK full-length cDNA. All the tested FRK mutants
induced a strong acute inflammatory response in hepatocellular
cell lines with overexpression of two inflammatory target genes,
SOCS3 and CRP, independently of interleukin-6 (IL-6) exposure
(Figure 2B; Figures S2A–S2C). This inflammatory response was
proportional to the amount of transfected mutants (Spearman’s
r = 0.89, p = 0.01; Figure S2B). FRK mutants induced the activa-
tion of STAT3 as assessed by its phosphorylation at Y705 and its
nuclear translocation, whereas wild-type FRK had no effect on
STAT3 phosphorylation and localization (Figures 2C and 2D).
We further showed that VF and FK FRK mutant exhibited an
increased kinase activity compared with the wild-type FRK,
affecting both Vmax and KM (Figure 2E; Figure S2D). Next, we
showed that four different Src inhibitors, namely, PP2, dasatinib,430 Cancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc.Src inhibitor 1, and Src inhibitor 5, were able to abrogate the
constitutive kinase activity of FRK mutants (Figure 2F). Then,
we selected dasatinib, an inhibitor currently used to cure leuke-
mia patients (Talpaz et al., 2006). Treatment of Hep3B cells with
dasatinib decreased the constitutive activity of FRK mutant in a
dose-dependent manner, whereas it had no effect on IL-6-
induced inflammation (Figure 2G).
Then, we stably transfected Ba/F3 cells, an interleukin-3 (IL-3)-
dependent murine pro-B cell line, with wild-type or mutant FRK.
In the presence of IL-3, cell proliferation was similar in all condi-
tions (Figure S2E); in contrast, only Ba/F3 cells expressing the
FRKmutants were able to grow upon IL-3withdrawal (Figure 3A).
We confirmed the proliferation advantage conferred by FRK
overexpression in mice immortalized fibroblasts, NIH 3T3,
cultured with a limiting amount of growth factors (Figure S2F).
Also, in NIH 3T3, FRK mutants promoted cell foci formation
without increasing cell migration or invasion (Figure 3B; Figures
S2G and S2H). Interestingly, in Ba/F3 cells, IL-3-independent
growth induced by FRK mutant was abrogated by dasatinib
treatment (Figure 3C). Subcutaneous injection of Ba/F3 cells
with stable expression of the VK FRK mutant in nude mice re-
sulted in tumor growth. In contrast, Ba/F3 cells expressing
wild-type FRK failed to promote tumor growth (Figure 3D). Allog-
rafted tumors showed nuclear and Y705-phosphorylated STAT3
(Figure 3E). Furthermore daily intraperitoneal injections of
dasatinib (10 mg/kg/day) after subcutaneous tumor develop-
ment and during 14 days led to a complete regression of the
tumors (n = 9; Figures 3F and 3G; Figure S2I). Interestingly,
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Figure 2. FRK Mutants Induce STAT3 Activation
(A) Spectrum of FRK mutations identified in 250 HCAs. Circles indicate amino acid (aa) substitutions and triangles are in-frame deletions. SH, Src homology
domain; TKD, tyrosin kinase domain.
(B) Endogenous SOCS3 mRNA expression of FRK mutants V378–F379 del (VF), V378–K380 delinsE (VK), E346G (E346), E346G Y350C (E346 Y350), V378
delinsKLN (VdelinsKLN), F379-K380 delinsL (FK), or control wild-type (WT) FRK (WT) and empty plasmid (EP) transfected in Hep3B. *p < 0.05; **p < 0.01; ***p <
0.001, two-tailed Student’s t test.
(C) Expression of FRK, total STAT3, and Y705-phosphorylated STAT3 (pSTAT3) proteins in transfected Hep3B cells assessed by western blot.
(D) Subcellular localization of FRK and tyrosine phosphorylation of STAT3 at Y705 (pSTAT3) FRK andSTAT3 proteins were analyzed by immunofluorescence, and
images were obtained with a confocal microscope. Results are representative of three independent experiments.
(E) FRK proteins WT and mutants (VF and FK) were produced in Escherichia coli. The AlphaScreen method showed an increased kinase activity for FRK mutants
with modified KM and Vmax. cps, counts per second.
(F) FRK kinase residual activity was measured in vitro by AlphaScreen method after treatment with four different Src inhibitors: PP2 (10 mM), dasatinib (10 mM),
Src-I1 (10 mM), and Src-I5 (10 mM). *p < 0.05, **p < 0.01, ***p < 0.001, two-tailed Student’s t test.
(G) Endogenous SOCS3mRNA expression of FRK VKmutant (blue) or empty vector treated with 100 ng/ml IL-6 (black) transfected in Hep3B exposed for 6 hr to
increasing concentrations of dasatinib. Quantitative data are presented as mean ± SD.
See also Figure S2.
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ing the oncogenic addiction of Ba/F3 cells to the FRK mutant
tested (Figure 3G).
Mutations Activating JAK-STAT3 Pathway in IHCA
Exome sequencing of an inflammatory adenoma revealed a
somatic missense mutation leading to S703I substitution in the
JAK kinase JAK1 previously identified in an acute lymphoblastic
T cell leukemia (Zhang et al., 2012). Screening the entire
sequence of JAK1 in the whole series of 250 tumors revealed
one additional IHCAwith a heterozygous somatic JAK1 substitu-tion A723D never described in tumors (Figure 1D; Figure 4A;
Table S5). S703I and A723D mutants were different from the
two classical V658 and R724 JAK1 substitutions known to acti-
vate the JAK-STAT pathway (Flex et al., 2008; Staerk et al.,
2005). In Hep3B cells, we showed that expression of S703I or
A723D was able to induce an inflammatory response and phos-
phorylation of STAT3 at Y705 (Figure 4B; Figures S3A and S3B).
Moreover, the two JAK1mutant proteins were phosphorylated at
Y1022/1023, two regulatory tyrosines known to activate JAK1
when phosphorylated (Figure S3B). We also identified in an in-
flammatory HCA an unusual heterozygous somatic mutation inCancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc. 431
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Figure 3. FRK Is a Targetable Activated Gene in HCA
(A) Growth of Ba/F3 cells stably transfected with FRK mutants (VF and VK) compared with FRK WT or EP after IL-3 withdrawal in triplicate experiments. Data
shown indicate mean ± SD.
(B) Cell foci formation was observed in NIH 3T3 cells stably expressing FRK mutants VF (p = 0.003, t test) or E346 (p = 0.0009, t test) and not in cells transfected
with WT FRK or EP. In white, the number of foci representative of three independent experiments.
(C) Ba/F3 cells transfectedwith FRK VKmutant treated (red) or untreated (blue) with 10 ng/ml IL-3 and exposed for 48 hr to increasing concentrations of dasatinib.
The graph plots the proportion of treated cells relative to the transfected not-treated cells.
(D) Subcutaneous injection of 107 Ba/F3 cells with stable expression of VK FRK mutant (blue, n = 9) induced tumor growth in a BALB/c-nu/nu mouse model,
whereas WT FRK (green, n = 6) failed (mean tumor volume, 95% CI, regression analysis).
(E) Representative staining of Y705 phosphorylation of STAT3 using immunohistochemistry in allograft tumors from VK FRK Ba/F3 cells 34 days after injection.
(F) Effect of dasatinib treatment on tumor size of mice allografted with Ba/F3 cells transfected with VK FRK mutant and treated daily with dasatinib (red, n = 9;
10 mg/kg/day) or with PBS as a control (blue, n = 9) (mean tumor volume, 95% CI, regression analysis).
(G) Effect of dasatinib withdrawal on allograft tumors from VK FRK Ba/F3 cells. Shown are the tumors of BALB/c-nu/nu mice treated daily with PBS (10 ml/kg,
14 days) as a control or with dasatinib (10 mg/kg/day, 14 days), and tumors treated with dasatinib during 14 days and left without treatment for 14 days (n = 3).
Scale (white) bars, 10 mm.
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Genomics of Hepatocellular Adenomathe IL6ST gene, located at exon 10 and leading to the in-frame
deletion of four amino acids (A418–F421) outside the mutation
hot spot that we previously identified at the IL-6 binding site432 Cancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc.(Poussin et al., 2013; Rebouissou et al., 2009). Sequencing the
entire coding sequence of IL6ST in the validation set of 250
tumors led to the identification of a similar A418–F421 deletion
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Figure 4. Identification of Uncommon Recurrent Gene Mutations in HCA and Functional Analysis
(A) Spectrum of JAK1 mutations identified in 250 HCAs. Circles indicate aa substitutions.
(B) JAK1 mutants S703I (S703) and A723D (A723) or control WT JAK1 (WT) and EP were transfected in the Hep3B cell line. Graphs are quantitative (q)RT-PCR
results showing the induction of endogenous SOCS3 mRNA transcription measured after 6 hr of serum starvation and, when indicated, treated for 3 hr
with 100 ng/ml IL-6 relative to unstimulated EP-transfected Hep3B cells. Data shown indicate mean ± SD. **p < 0.01, ***p < 0.001, two-tailed Student’s t test
versus WT JAK1.
(C) Spectrum of CTNNB1 mutations identified in 250 HCA. Circles indicate aa substitutions, and triangles are in-frame deletions. ARM, Armadillo repeat; TAD,
transactivation domain.
(D)CTNNB1mutants S33Y (S33), T41A (T41), S45P (S45), K335I (K335), and N387K (N387) or control WTCTNNB1 (WT) and empty plasmid (EP) were transfected
in Huh7 cells expressing aCTNNB1-driven luciferase (TOP-FLASH) reporter construct. Shown is the luciferase activity determined from triplicate cotransfections
relative to empty plasmid (EP). Data shown indicate mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001, two-tailed Student’s t test versus WT CTNNB1 with TOP-
FLASH.
(E) Expression profiles of CTNNB1-exon 3mutated HCA (n = 45),CTNNB1-exon 7- and -exon 8-mutated HCAs (n = 21) andCTNNB1WTHCA (n = 169). The graph
shows the expression of GLUL (glutamine synthase) and LGR5 by qRT-PCR relative to nontumor livers. Results are expressed as Tukey’s boxplots; two-tailed
Mann-Whitney test.
(F) Representative staining of glutamine synthase (GS) by immunohistochemistry in wild-type CTNNB1 HCA, exon 7-mutated and exon 3-mutated bHCA.
*p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S3.
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IL6ST were exclusive from the classical mutation previously
identified in exon 6. We further showed that this IL6ST mutant
was able to constitutively activate gp130 in a cell culture model
(Figure S3C). Finally, in the entire validation set of HCA, all the
genes mutated in IHCA (IL6ST, FRK, JAK1, STAT3, and GNAS)
were almost mutually exclusive; only one tumor showed muta-
tions in both FRK and STAT3 genes (Figure 1D).
Hot Spots of Mutations in CTNNB1
Exome sequencing in two HCAs revealed amutation ofCTNNB1
located in exon 7 (K335I), outside CTNNB1 exon 3 where the
classical mutations activating b-catenin are usually located
(Chen et al., 2002). Among the validation set of 250 tumors, we
further identified two hot spots of substitutions at b-catenin
codon 335 (K335I in 13 cases, K335T in four cases) and codon
387 located in exon 8 (N387K in six cases; Figure 4C). AllHCAs with CTNNB1 exon 7 and exon 8 mutations were previ-
ously considered as unclassified HCA (seven cases) or inflam-
matory adenoma (16 cases), and they were further classified
for all analyses in the bHCA or bIHCA molecular subgroup.
CTNNB1 exon 7 and exon 8 mutations were mutually exclusive
but also frommutations located at exon 3 andHNF1Amutations.
We further showed that K335I and N387K mutants were able to
activate b-catenin in a hepatocellular cell line, with a lower activ-
ity than the S33Y, T41A, and S45Pmutants located within exon 3
(Figure 4D). Accordingly, most of the HCA tumors with exon 7 or
exon 8 mutation exhibited a slight overexpression of glutamine
synthase and LGR5, two classical genes activated by CTNNB1
(Figure 4E). Immunohistochemical analyses of these cases
revealed a faint patchy glutamine synthase expression without
nuclear staining of b-catenin (Figure 4F). All these results showed
that CTNNB1 mutants at codons 335 and 387 weakly activate
b-catenin in vivo in HCA.Cancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc. 433
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Figure 5. SNP Array Profiling of HCA Reveals Distinct Copy-Number Profiles Associated with Molecular Groups
(A) Distribution of genomic instability, defined as the FAA, in different molecular groups. Results are expressed as Tukey’s boxplots; two-tailed Mann-Whitney
test. ns, not significant
(B) Distribution of chromosome aberrations according to HCA molecular classification groups. LOH of chromosome 12q significantly associates with H-HCAs,
whereas gains of 1q and of chromosome 7 associate with bHCA.
(C) Frequency of gains, deletions, and LOHs along the genome in a series of 111 classical HCAs, nine borderline lesions HCA/HCC, and six HCCs resulting from
HCA malignant transformation.
See also Table S7.
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Weprofiled chromosome aberrations in 111 classical HCAs, nine
borderline lesions HCA/HCC, and six HCC resulting from HCA
malignant transformation. Although chromosomal instability,
measured by the fraction of aberrant arms (FAA) score, was
low and similar in the different molecular subgroups of classical
adenomas (Figure 5A), we identified three recurrent events asso-
ciated with specific molecular groups: bHCA showed more
frequent gains of 1q (p = 0.03) and chromosome 7 (p = 0.03),
whereas H-HCA presented frequent copy-neutral losses of
heterozygosity (LOHs) at chromosome 12q, leading to a loss of
thewild-typeHNF1A gene and a duplication of themutated allele
(p = 3.4 3 106; Figures 5B and 5C; Table S7).
We then determined DNA methylation profiles in 50 hepa-
tocellular adenomas and four normal liver samples using
HumanMethylation450 arrays (Illumina). Consensus clustering
identified two major clusters closely associated with the inflam-
matory phenotype (M1 and M2) or noninflammatory phenotypes
(M3–M5). The partition in the five stable DNA methylation clus-
ters (Figure 6A, M1–M5) was highly associated with specific
molecular groups (p = 3.4 3 1019, chi-square test; Figure 6B)
and gene mutations. The M1 cluster included IHCA and mixed
bIHCAs exclusively mutated in exon 7 or exon 8 of CTNNB1,
whereas the M2 cluster included bIHCAs mutated in exon 3.
Noninflammatory tumors were subdivided in clusters M3 in-
cluding all H-HCA, M4 including most bHCA, and M5 including
UHCA. Most DNA methylation changes occurred at CpG
sites located outside CpG islands that displayed global hypome-
thylation in all tumor clusters compared with normal controls
(Figure S4A). As described in HCC (Stefanska et al., 2011), hypo-434 Cancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc.methylated regions formed genomic clusters, preferentially
located at gene family loci (Figure S4B). Although the pattern
of hypomethylation was similar in the five tumor clusters, the in-
tensity of hypomethylation was significantly associated with
methylation clusters (p = 2.1 3 104, ANOVA). Hypomethylation
was weaker in clusters M1 and M2 (inflammatory HCA) and
stronger in cluster M4 (bHCA), particularly in tumors that trans-
formed into HCC (Figure 6C). There were few hypermethylated
CpG sites, but we identified 640 genes specifically hypermethy-
lated in cluster M3. Among them, 109 genes were hypermethy-
lated and downregulated in H-HCA (significant overlap, p =
2.4 3 1036, Fisher’s exact test) (Table S8); they were signifi-
cantly enriched in liver-specific genes (p = 9.73 106, hypergeo-
metric test) (Figure 6D) and in genes known to be downregulated
in liver cancer (Acevedo et al., 2008) (p = 1.73 1014, hypergeo-
metric test) (Table S9).
Alterations Involved in Malignant Transformation
Next, we aimed to investigate the genetic and epigenetic alter-
ations involved in malignant transformation of HCA to HCC.
We observed a progressively increased chromosomal instability
in borderline HCA/HCC lesions and in HCC derived from malig-
nant transformation compared with classical HCA (p = 0.05;
Figure 7A; Table S10). Specific loss of chromosome 6q and
gain of chromosome 7 were more frequent in borderline and
transformed HCA (Figure 5B). Interestingly, in methylome anal-
ysis, the intensity of the beta-value in hypomethylated genomic
regions increased during malignant transformation (p = 0.002,
ANOVA) (Figure 7B). Exome sequencing and SNP array
analysis (Letouze´ et al., 2010) were carried out in five cases of
A B
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Figure 6. DNA Methylation Analysis of HCA Reveals Strong Correlation with Molecular Groups
(A) Consensus clustering analysis of 50 HCAs identifies five DNA methylation clusters.
(B) Heatmap representation of DNA methylation profiles. FDR, false discovery rate.
(C) Boxplots represent the mean DNA methylation beta-values in hypomethylated clusters in tumors of different methylation subgroups.
(D) DNA methylation and gene expression are represented for 13 liver-specific genes that are significantly hypermethylated and downregulated specifically
in H-HCA.
See also Figure S4 and Tables S8 and S9.
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Genomics of Hepatocellular Adenomasynchronous malignant transformation for which both benign
(HCA) and malignant (HCC) parts of the tumors were available.
In comparison with classical HCA, the number of functional
somatic mutations progressively increased in transformed HCA
(mean of 24.4 events per transformed HCA, p < 0.0001; Fig-
ure 7C) and in malignant HCC part of the tumors (mean of 39
events per HCC counterpart) at a level similar to that observed
previously in a series of classical HCC (Guichard et al., 2012)
(Figures 7C and 7D). In four cases, mutations in the genes clas-
sically mutated in HCA (CTNNB1, IL6ST, and HNF1A) were
similar in the HCA and HCC counterparts, demonstrating a com-
mon origin of the benign and transformed parts of the tumors
(Figure 7G; Figure S5A). In the fifth case, the HCA and HCC parts
showed different CTNNB1 mutations, whereas 43 other muta-
tions were found in common.
Among the other genes recurrently mutated in transformed
HCA, we identified in two cases ASH1L (recurrently mutated
in lung cancers and cell lines (Govindan et al., 2012; Liu
et al., 2012) and PEG3, which is mutated in cholangiocarci-
noma (Ong et al., 2012) (Figure S5B). A large number of private
mutations were also accumulated in almost all HCA and HCCtumors, illustrating separated genetic evolution. Interestingly,
in case 361, we also analyzed an HCC relapsed 3 years after
the first surgical resection of a transformed HCA. Only one
mutation activating b-catenin (CTNNB1 in-frame deletion
T3_A126) was common between the HCA tumor, the synchro-
nous HCC, and the relapsed HCC. Moreover, in this patient,
we identified in three different samples of nontumor liver tis-
sues a similar T3_A126 CTNNB1 deletion in 1/10,000 tested
cells (Figure S5C). These results pointed CTNNB1 mutation
as a very early tumorigenic event in a precursor cell niche
that generated three different tumors. In this case we also
identified in each tumor a different mutation in the gene coding
for the monoamine oxidase MAOB, suggesting that the inhibi-
tion of this gene was selected to promote the tumor
development.
In the mutation screening, we added the telomerase reverse
transcriptase (TERT) promoter, not covered in exome
sequencing, because hot spot mutations were recently identi-
fied in various tumors, including HCC (Horn et al., 2013; Huang
et al., 2013; Killela et al., 2013; Nault et al., 2013b). TERT pro-
moter mutations were identified in five samples and in most ofCancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc. 435
Figure 7. Time Frame of Genomic Alterations in HCA Malignant Transformation
(A) Distribution of chromosomal instability, defined as the FAA, in different pathological groups (maximum-minimum [max.-min.] boxplot, two-tailed Mann-
Whitney test).
(legend continued on next page)
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Genomics of Hepatocellular Adenomathe cases (four of five) only in the malignant parts, suggesting
that TERT promoter mutations could be a later oncogenic
event after CTNNB1 mutations. Then, we screened TERT pro-
moter in a large series of 375 hepatocellular tumors, including
223 classical adenomas, 18 borderline lesions HCA/HCC, nine
HCC derived from adenomas, and 125 classical HCC (Gui-
chard et al., 2012). TERT promoter mutations were not found
in classical adenomas, but they were found later in the malig-
nant progression in borderline lesions (17%) and in trans-
formed HCA to HCC (56%) with a frequency similar to that
identified in classical HCC (54%). In HCC, TERT promoter mu-
tations were significantly associated with CTNNB1 mutations
(p < 0.0001). Previous studies have shown that TERT promoter
mutations create de novo consensus binding sequence for
ETS/TCF transcription factors and could increase telomerase
transcription (Horn et al., 2013). Here, in HCA, borderline
lesion, and transformed HCA, TERT promoter mutations
were significantly associated with an increased transcription
of TERT (p < 0.0001; Figure 7F). Then, we compared the dis-
tribution of all recurrent gene mutations in the overall set of
375 tumors (Figures 7E and 7H). The proportion of CTNNB1
exon 3 and CTNNB1 exon 3 associated with IL6ST mutations
progressively increased from the adenoma (13%) to the HCC-
transformed lesions (66%), thus showing the significant role of
these mutations in malignant progression. In contrast, the pro-
portion of IL6ST alone, CTNNB1 exon 7 and exon 8, HNF1A,
and FRK mutations decreased in HCA transformed in HCC
and was also lower in classical HCC, suggesting that these
genes are not significantly involved in malignant transformation
process.
By integrating all the omic results with the clinical and patho-
logical features and with the identification of FRK, rare JAK1,
and exon 10 IL6ST-activating mutations, we have enriched the
mutational spectrum of inflammatory HCA, finally composed of
mutations in IL6ST (26% of HCA), FRK (5%), STAT3 (2%),
GNAS (2%), and JAK1 in 1% (Figure 8A). Three pathways recur-
rently altered in HCA (HNF1A inactivation, STAT3 or b-catenin
activation alone) are associated with the benign phenotype of
the tumors and specific histological features (Figure 8B). In
contrast, the malignant transformation is strongly associated
with characteristic gene mutations (CTNNB1 exon 3 and TERT
promoter mutations), chromosome alterations, and hypomethy-
lation accumulated in time frame together with previously
described specific clinical features (male sex and androgen
therapy, Nault et al., 2013a; Figure 8C).(B) Boxplots represent the mean DNA methylation beta-values in hypomethyl
Wallis test).
(C) Number of damagingmutations in classical HCA, in HCA transformed in HCC (H
and in 24 classical HCC(Guichard et al., 2012) (max.-min. boxplot, two-tailed Ma
(D) Paired comparison of HCA and HCC counterparts of five malignant transform
(E) Distribution of the pathological groups of tumors mutated in TERT promoter, e
IL6ST without CTNNB1 mutation, exon 7 and exon 8 of CTNNB1, and HNF1A (c
(F) TERT expression in mutated and nonmutated TERT promoter tumors accord
(G) Accumulation of genomic alterations in five malignant transformations was
indicates genes recurrently mutated in transformed HCA, blue indicates genes
mosomal alterations.
(H) Frequency of mutations in TERT promoter, exon 3 ofCTNNB1without IL6STm
exon 7 and exon 8 of CTNNB1, and HNF1A according to the pathological group
See also Figure S5 and Table S10.DISCUSSION
Whole-exome sequencing of hepatocellular adenomas revealed
the high genetic diversity of these tumors, and the genes recur-
rently mutated in hepatocyte benign tumorigenesis and in the
subsequent malignant transformation. In this study we identified
recurrent somatic mutations of FRK leading to an activation of
the FRK kinase activity and to constitutive STAT3 activation
associated with the inflammatory phenotype of HCA. Whereas
the activation of STAT3 by Src has been previously described
in vitro (Bromberg et al., 1998; Turkson et al., 1998), we showed
that FRKmutants induce STAT3 activation in vitro, in vivo, and in
human tumors. Also, whereas FRK has been proposed as a
tumor suppressor in breast cancer (Yim et al., 2009), here we
demonstrated the proproliferative function of mutant FRK during
benign tumorigenesis. In the liver, FRK mutants were identified
only in benign tumors, whereas mouse models of gastrointes-
tinal cancer have also demonstrated opposite functions of
STAT3 at early step of tumorigenesis and duringmalignant trans-
formation (Grivennikov and Karin, 2010; Lee et al., 2012; Mus-
teanu et al., 2010). However, FRK was also reported as involved
in a chromosome rearrangement with ETV6 in a leukemia
(Hosoya et al., 2005), suggesting that this gene could be as
well activated in malignant neoplasms. Also, the oncogenic
properties of STAT3 constitutive activation could differ accord-
ing to the cell of origin related to a malignant cell proliferation
in lymphocytes (Fasan et al., 2013; Koskela et al., 2012) versus
benign proliferation in hepatocytes mutated for IL6ST or
STAT3 (Pilati et al., 2011; Rebouissou et al., 2009). In addition,
the dramatic response to the Src inhibitor dasatinib in vitro and
in vivo supports FRK-activating mutations as a paradigm of a
mutated gene addiction. Overall, the gene mutations identified
in IHCA activate the STAT3 pathway to cause a common inflam-
matory phenotype within the tumors. Nowadays, inflammatory
driver gene mutations remain to be identified in 18% of inflam-
matory HCA. Moreover, 10% of the adenomas remain unclassi-
fied and in these cases additional specific genetic or epigenetic
defect remained to be identified.
Interestingly, our methylome analysis distinguished perfectly
the five molecular groups of HCA, and identified genomic clus-
ters of hypomethylation at gene family loci showing a close
relationship between epigenetic changes, gene mutations, and
phenotypes of the tumors. We also identified a set of liver-
specific genes, hypermethylated and downregulated specifically
in H-HCA. A previous report suggested that activation of HNF1Aated clusters in tumors of different pathological stages (two-tailed Kruskal-
CA part) and in HCC resulting from a transformation of an adenoma (HCC part)
nn-Whitney test).
ations (two-tailed paired t test).
xon 3 of CTNNB1 without IL6STmutation, both exon 3 of CTNNB1 and IL6ST,
hi-square test).
ing to the different pathological stages (two-tailed Mann-Whitney test).
defined according to whole-exome sequencing and SNP array analysis. Red
recurrently mutated in classical HCA, and in green indicates recurrent chro-
utations, both exon 3 ofCTNNB1 and IL6ST, IL6STwithoutCTNNB1mutations,
s.
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Figure 8. Genes and Pathways Implicated in HCA Initiation and Malignant Transformation
Major pathways (A) commonly altered by somatic mutations in classical HCA. Alteration frequencies are expressed as a percentage of mutation in the validation
series of 250 tumors (red or blue when activated or inactivated, respectively) or 35 exome-sequenced (gray) HCAs; for unique gene mutation, no frequency is
indicated. Arrows are positive interactions between two genes. Integration of the major genomic alterations occurring in classical HCA (B) and in malignant
transformation of HCA in HCC (C).
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demethylation (Pontoglio et al., 1997). Alternatively, active tran-
scription could protect CpG islands from methylation, so hyper-
methylation may be a consequence of prior gene silencing (Clark
and Melki, 2002). Further experiments are needed to determine
whether DNA hypermethylation precedes or follows the silencing
of liver-specific genes in H-HCA, but these epigenetic changes
are likely to play an active role in this molecular group of HCA,
and they suggest that driver genetic alterations could induce
widespread epigenetic modification in hepatocellular benign
tumors.
Analysis of the progression from HCA to HCC suggested
that the occurrence of CTNNB1-activating mutation in a single
cell could initiate benign liver tumorigenesis as a very early
event in patient 361. However, because almost all the ade-
nomas activated for b-catenin accumulate additional mutation
in recurrent (IL6ST) or nonrecurrent genes, it is highly sugges-
tive of the requirement of additional events to CTNNB1 acti-
vating mutation to promote a benign clonal proliferation.438 Cancer Cell 25, 428–441, April 14, 2014 ª2014 Elsevier Inc.These results are in accordance with the transgenic mouse
model of hepatic CTNNB1 mutant expression in which the
constitutive Wnt pathway activation is not sufficient for hepa-
tocarcinogenesis (Cadoret et al., 2001; Harada et al., 2002).
As in other tumor types (Vogelstein et al., 1988), accumulation
of chromosome aberrations is also a typical feature of malig-
nant transformation of HCA. Here, in hepatocellular tumors,
we identified somatic-activating TERT promoter mutations as
a major event involved in the malignant transformation of he-
patocellular adenomas in association with b-catenin activation.
These results suggest a step-by-step model where CTNNB1
mutations are early mutational events in benign liver tumori-
genesis, although not sufficient to induce HCC in normal liver
alone; telomerase reactivation through TERT promoter muta-
tions is consequently required to promote full malignant trans-
formation. Identification of CTNNB1 and TERT promoter muta-
tion as key genetic determinants of malignant transformation
in HCA will be useful to propose tailored treatment in these
subtypes of patients.
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Genomics of Hepatocellular AdenomaIn conclusion, we reported a comprehensive genomic analysis
of hepatocellular adenoma resulting from the benign proliferation
of hepatocytes and their malignant transformation in hepatocel-
lular carcinoma. Integrated analyses revealed the high robust-
ness of the HCA molecular classification: all subclasses of
tumors defined by the different omics are closely related
together and with HCA tumor phenotypes. In addition, this clas-
sification will have clinical impact through identification of
therapeutic targets and the selection of patients with high risk
of malignant transformation that could require more aggressive
treatment.
EXPERIMENTAL PROCEDURES
Liver Samples and Clinical Data
All tumors and corresponding nontumor liver tissues were frozen after surgical
resection. These tumors were clinically and genetically characterized; they
were previously included in genetic and phenotypic studies (Tables S1 and
S2). The study was approved by the local Ethics Committee (Paris Saint-
Louis), INSERM institutional review board in 2010, and informed consent
was obtained from all subjects in accordance with French legislation. HCA
were classified in (1) H-HCA according to the presence of HNF1A inactivation
(73/250, 29%); (2) bHCA defined by a somatic b-catenin-activating mutation
involving exon 3 and/or an overexpression of glutamine synthase and LGR5,
two b-catenin target genes (53/250, 21%); and (3) IHCA defined by the pres-
ence of inflammatory infiltrates and a serum amyloid A2 and C-reactive protein
overexpression (118/250, 47%); in 25 cases (10%), HCAswere both inflamma-
tory and CTNNB1 mutated (bIHCA). The remaining 31 cases (12%) were
unclassified HCA (UHCA) when we began this study.
Genomic Analysis
Whole-exome sequencing was performed as described previously (Guichard
et al., 2012). The false-positive rate of somatic mutations in WES was
estimated to 2.5% after 3,000 verifications in Sanger sequencing per-
formed in previous analyses. Comparative genomic hybridization-SNP was
performed on 126 tumors with HumanCNV370-Duo v1.0 (47 tumors) or
HumanOmniExpressBeadchips (79 tumors) (both from Illumina). When several
samples were available from a same patient, tumor progression trees were
reconstructed using the TuMult algorithm (Letouze´ et al., 2010). DNA methyl-
ation profiles of 50 hepatocellular adenomas and four normal liver
samples were determined using HumanMethylation450 arrays (Illumina). The
ConsensusClusterPlus package (Bioconductor) was used for consensus clus-
tering analysis. Transcriptional profiling experiments were performed using
oligonucleotide GeneChips HG-U133A (Affymetrix).
Functional Analysis
FRK, JAK1, IL6ST, and CTNNB1 mutants were obtained using the
QuickChange XL site-directed mutagenesis kit (Stratagene) using primers
described in Supplemental Experimental Procedures, and then used to tran-
siently transfect Hep3B, Huh7, NIH 3T3, and Ba/F3 cells. Ba/F3- and NIH
3T3-transfected cells were selected by a treatment with Geneticin (800 and
700 mg/ml, respectively; Life Technologies). Kinase assay was performed by
AlphaScreen-based assays (PerkinElmer). BALB/c-nu/nu mice used for
xenograft experiments were housed in the pathogen-free animal facility at
the Institut Universitaire d’He´matologie, Paris. All experimental procedures
were done in compliance with the French Ministry of Agriculture regulations
for animal experimentation.
A complete description of the materials and methods is provided in Supple-
mental Experimental Procedures.
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